Marksans Pharma Limited has informed the Exchange regarding a press release dated November 17, 2025, titled "Marksans Pharma Limited's wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its Products from UK MHRA.".
Marksans Pharma Limited has informed the Exchange regarding a press release dated November 17, 2025, titled "Marksans Pharma Limited's wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its Products from UK MHRA.".